IRVING, Texas--(BUSINESS WIRE)--MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (OTCBB:RBCL), announced the initiation of human clinical trials, in three medical institutions, designed to evaluate the efficacy of its topical wound gel, Regenecare™, in the relief of painful, itching skin rashes that occur as a side effect during treatment by a group of widely-used cancer drugs known as epidermal growth factor receptor (EGFR) inhibitors.
